

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

**Title:** Evaluation of Different Types of Face Masks to Limit the Spread of SARS-CoV-2 – A Modeling Study

**Authors:** Brian M. Gurbaxani, PhD<sup>1\*</sup>; Andrew N. Hill, PhD<sup>2\*</sup>; Prabasaj Paul, PhD<sup>3</sup>; Pragati V. Prasad, MPH<sup>3</sup>; Rachel B. Slayton, PhD<sup>3</sup>.

\*These authors contributed equally to this work

**Affiliations:** Centers for Disease Control and Prevention, Atlanta, Georgia, USA

**Article Summary Line:** Adapting a published SARS-CoV-2 transmission model together with updated, laboratory-derived source control and wearer protection efficacy estimates for a variety of face coverings as well as N95 respirators, we demonstrate that community masking as currently practiced has likely reduced cases and deaths and that this benefit can be increased with wider adoption of better performing masks.

**Running Title:** Evaluation of Face Masks to Limit SARS-CoV-2

**Keywords:** 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; coronavirus; mathematical modeling; severe acute respiratory syndrome coronavirus 2; face masks.

**All text:** Times New Roman 12-pt. font; double-spaced and left aligned (left-justified).

**Manuscript Number:**

21 **Abstract – (Word Count 149):**

22 We updated a published mathematical model of SARS-CoV-2 transmission with laboratory-  
23 derived source and wearer protection efficacy estimates for a variety of face masks to estimate  
24 their impact on COVID-19 incidence and related mortality in the United States. When used at  
25 already-observed population rates of 80% for those  $\geq 65$  years and 60% for those  $< 65$  years, face  
26 masks are associated with 69% (cloth) to 78% (medical procedure mask) reductions in  
27 cumulative COVID-19 infections and 82% (cloth) to 87% (medical procedure mask) reductions  
28 in related deaths over a 6-month timeline in the model, assuming a basic reproductive number of  
29 2.5. If cloth or medical procedure masks' source control and wearer protection efficacies are  
30 boosted about 30% each to 84% and 60% by cloth over medical procedure masking, fitters, or  
31 braces, the COVID-19 basic reproductive number of 2.5 could be reduced to an effective  
32 reproductive number  $\leq 1.0$ , and from 6.0 to 2.3 for a variant of concern similar to delta  
33 (B.1.617.2).

34

35 **Text – (Word Count 3304)**

36 **Introduction:**

37 The emergence of coronavirus disease 2019 (COVID-19) has had a substantial impact on  
38 populations globally, with efforts across governments to prevent its remarkable spread. While  
39 social distancing has been universally recommended since very early in the pandemic,  
40 recommendations for masks in the general population were adopted later in many countries (see,  
41 for example, [1]). Several factors contributed to the initial uncertainty around the potential  
42 impact of widespread use of face masks on SARS-CoV-2 transmission. A large and well-  
43 designed 2015 study on cloth face masks (the main type of mask available to the public at the

44 time) contributed to the scientific uncertainty that these types of face coverings were effective for  
45 preventing the transmission of respiratory diseases [2]. There were initial hypotheses that cloth  
46 masks could give the wearer a false sense of protection and even contaminate the wearer with  
47 accumulated viral particles, notably described in a high-profile study in the *Annals of Internal*  
48 *Medicine* that was later retracted (for failure to note PCR assay values that were below the limit  
49 of detection) [3]. Furthermore, a major concern at the beginning of the outbreak in the US was  
50 supply, especially of high-quality masks like N95 respirators. As it became clear, however, that  
51 the virus can spread through exhaled respiratory droplets from infected individuals without  
52 symptoms [4], the U.S. Centers for Disease Control and Prevention (CDC) recommended masks  
53 for general use early in the U.S. pandemic (as of April 2020, [5]). Evidence continues to show  
54 that asymptomatic and clinically mild infections contribute substantially to SARS-CoV-2  
55 transmission [6-9]. Together, this growing body of evidence has highlighted the importance of  
56 prevention measures, like masking, to reduce transmission from people who are asymptomatic,  
57 undetected, or both.[6-8].

58 As the COVID-19 pandemic has continued, evidence has accumulated that face mask use by the  
59 general population can limit the spread of SARS-CoV-2. This evidence has taken three main  
60 forms, described in order of their appearance in the literature: 1) modeling studies that suggested  
61 that even if masks are limited in their efficacy, widespread use across the population could still  
62 reduce the spread of the virus to a considerable degree [10, 11], 2) laboratory studies that  
63 demonstrated masks physically block exhaled droplets and aerosols containing virus from  
64 infected persons (source control) and also offer wearer protection [12-14], and 3)  
65 epidemiological studies that documented lower transmission in settings where masks were used  
66 [15-19]. In this study, we extend the model of Worby and Chang to use age-stratified social

67 contact patterns for the general U.S. population, and we analyzed the model both employing the  
68 measured face mask efficacy parameters for a variety of specific types of masks and for efficacy  
69 estimates that can act as benchmarks for evaluating these products [20].

70

## 71 **Methods:**

72 We adapted the transmission model (used for studying resource allocation of masks) of Worby  
73 and Chang (2020) for face mask adoption in a hypothetical population by expanding it to the  
74 age-stratified social contact patterns characteristic of the demographic profile of the United  
75 States. The underlying structure of this compartmental model is described in Worby and Chang  
76 [20], which we briefly summarize. Individuals are classified according to their disease status and  
77 whether or not they wear a mask in public. The model is further stratified by age in 5-year age  
78 bands. People contact each other (defined as either direct physical contact, e.g. through a  
79 handshake or a kiss, or a proximal, two-way conversation of 3 or more words) at age-specific  
80 daily rates estimated for the United States, as described by Mossong et al. and Prem et al. [21,  
81 22]. We compared the results of the model with the age stratification removed, and the results  
82 were significantly different (data not shown). Given that the infection fatality ratios (IFRs) are  
83 strongly age structured, we believe the age stratification is appropriate. Vaccination is not  
84 explicitly part of the model and has not been included in this study.

85

86 A schematic of the compartmental model is shown in Figure 1. Susceptible individuals who are  
87 infected move into an exposed compartment and thereafter into a pre-symptomatic compartment.  
88 Subsequently, a pre-specified proportion of these individuals moves into an asymptomatic state,  
89 while the remainder become fully symptomatic. Pre-symptomatic, asymptomatic, and fully

90 symptomatic SARS-CoV-2 infected individuals all contribute to the force of infection with  
91 varying degrees of infectiousness. All asymptomatic individuals recover, whereas a proportion of  
92 fully symptomatic individuals do not recover and die. A fraction of asymptomatic cases is  
93 assumed to be detected whereupon a fraction of these individuals begins to use a mask and  
94 continue to mask thereafter. Similarly, a fraction of symptomatic cases is assumed to know they  
95 have COVID-19, and these individuals put on a mask at the same adoption level as detected in  
96 asymptomatic cases. Symptomatic persons and detected, asymptomatic persons who wear a  
97 mask also change their contact rates reflective of some degree of isolation/quarantine. We do not  
98 include specific compartments modeling quarantine per se, but rather we reduce contact rates  
99 which accomplishes the same purpose and maintains simplicity of compartmental structure while  
100 allowing a degree of mixing that might be anticipated among a fraction of infected individuals  
101 who are not strictly isolating themselves. We also assumed a fraction of the general population  
102 adopts mask usage at the outset and continues usage regardless of infection status. Other than the  
103 aforementioned masked cases, we assumed that contact rates among age groups remain the same  
104 when people wear a mask. A basic reproduction number ( $R_0$ ) of 2.5 was assumed in the absence  
105 of any mask use, consistent with CDC's pandemic planning scenarios [23]. We also explored the  
106 model with a basic reproduction number of 4.0, in keeping with the estimated magnitude of the  
107 B.1.1.7 variant [24]. The modeled time horizon was 6 months and the cumulative number of  
108 infections and deaths were recorded. The impact of various levels of mask adoption was assessed  
109 by calculating the relative reduction in cumulative infection and deaths, comparing cumulative  
110 cases and deaths to the same model over the same time horizon with no mask use in the entire  
111 population.

112 Masks were modeled to reduce transmission via two different mechanisms: source control  
113 efficacy, whereby mask wearing by an infectious person reduces their likelihood of transmitting  
114 SARS-CoV-2; and wearer protection efficacy, whereby masks protect a susceptible person from  
115 becoming infected when exposed to an infectious person. We examined adoption of various  
116 kinds of masks (e.g., cloth, medical procedure, N95 respirators) specifically incorporating  
117 estimates from a recent study of source control efficacy [14]. A range of values of hypothetical  
118 wearer protection efficacy was assumed for each kind of mask. Although it has generally been  
119 found that wearer protectiveness coefficients are approximately half the source control values  
120 [13, 25, 26], wearer protection efficacy was allowed to vary in the plot because it could be  
121 greatly affected by how the mask is worn, maintained, and used. Characteristics of each mask  
122 when worn according to manufacturers' specifications can be found in Lindsley et al. and are  
123 shown in Table 1 [14]. We do not address the issue of mask and respirator use in healthcare  
124 settings in this paper, as there is substantial public health guidance regarding the use of personal  
125 protective equipment in healthcare settings [27].

126

## 127 **Results:**

128 Figure 2 depicts heat maps of reduced transmission and deaths over 6 months as a function of  
129 varied source control efficacy and wearer protection efficacy. Mask wearing rates by the various  
130 sub-populations in the model are provided in the figure caption. These rates were in line with  
131 surveys of mask usage in the United States in May and June 2020 [28]. The colored bands of the  
132 plots represent contours of relative reduction. Going from the bottom left corner of the figures  
133 (source control efficacy and wearer protection efficacy both 0%, equivalent to no mask wearing  
134 in the population) these increase in 5% increments to the right top corner (source control efficacy

135 and wearer protection efficacy both 100%). For example, to obtain at least a 50% reduction in  
136 cumulative infections, source control would need to be at least 55% efficacious in limiting  
137 transmission in the population for arbitrary wearer protection efficacy. Source control would  
138 need to be approximately 45% effective to reduce the number of deaths by half regardless of  
139 wearer protection efficacy.

140 Even with the source control and wearer protection efficacy for the types of mask that most  
141 wearers are likely to use, such as medical procedure or cloth masks and gaiters (see Table 1),  
142 substantial reductions in case load and death can be achieved with general population use at  
143 stated levels. Even at lower levels of use, reductions are estimated to be substantial. As source  
144 control and wearer protection efficacy approach 100% for the masks, relative reduction in  
145 infections also approaches 100%, even though mask adherence is far from 100%, because  
146 transmission dips below the epidemic threshold (i.e. an effective reproduction number  $< 1$ ). Our  
147 simulations project that a 70% reduction in cumulative infections, relative to zero mask usage,  
148 could be achieved with hypothetical combinations of wearer protection and source control  
149 efficacies, respectively, of (0%, 65%), (25%, 50%), (40%, 35%), (50%, 25%), among many  
150 others lying on the 70% contour curve of the left panel of Figure 2.

151 Figure 3 depicts the reduction in infections with different population-wide percentages of mask  
152 use, with the assumption that mask wearer protection efficacy is half of source control efficacy  
153 and that mask use among persons  $< 65$  years old is 70% that of persons  $\geq 65$  years old. We  
154 evaluated these impacts for SARS-CoV-2 (3A, left) and one of its highly contagious variants of  
155 concern (3B, right, for parameters similar to the Delta variant). Mask wearing rates for detected  
156 and infected people are fixed at 90% for those  $\geq 65$  years old, and 70% for those who are  
157 younger. Based on the model, in Figure 3A if 25% of the general population  $\geq 65$  years old puts

158 on a mask, cumulative cases after 6 months are reduced by 23% (N95), 14% (medical  
159 procedure), 12% (cloth), 12% (gaiter), and 9% (bandana). If mask adoption is 50% for the  
160 general population  $\geq 65$  years old, projected reductions in cases are 57% (N95), 32% (medical  
161 procedure), 28% (cloth), 28% (gaiter), and 20% (bandana). If mask adoption is 75% for  $\geq 65$   
162 years old, projected reductions in cases are 95% (N95), 65% (medical procedure), 55% (cloth),  
163 54% (gaiter), and 35% (bandana). Note that even with 0% mask use for the susceptible  
164 population (horizontal axis), there is still a significant measure of infection control because of  
165 mask adoption among detected infected people.

166 Figure 3B shows similar results to 3A, but assuming a much more highly contagious variant,  
167 similar to Delta (B.1.617.2) with an  $R_0 = 6.0$ . The results are dramatically different, and even a  
168 high degree of adoption of the highest efficacy masks does not completely stop transmission.  
169 Note that even if the susceptible population don masks at a 100% rate, the mask wearing rates of  
170 detected asymptomatic and infected people are fixed at 90% (for those  $> 65$ ) and 70% (for those  
171 younger) in the simulation, which helps explain the seemingly low performance of 100% mask  
172 wearing rate for N95 masks.

173 We estimated the incidence rate ratios (IRR) for new infections among mask wearers relative to  
174 non-mask wearers over the course of 6 months, for different types of mask (Table 2). These  
175 estimates reflect the impact of mask wearing on an individual wearer, whereas all of the other  
176 analyses in this paper are focused on the population-level impact. The IRR at a given point in  
177 time is the ratio of the number of new infections per capita among the mask wearing population  
178 to the corresponding number among the non-mask wearing population. This assumes equal  
179 mixing of masked and non-masked individuals – modeling the tendency for those populations to  
180 self-segregate would tend to decrease these IRR values. As expected, the greater the mask



181 efficacy, the greater the difference in new infection rates as measured by the IRR. After 6  
182 months, new infections are projected to occur at around half the rate among mask wearers  
183 compared to those not wearing N95 respirators, whereas in a scenario where medical procedure  
184 masks are worn, infections among mask wearers occur at around a 32% lower rate.

185 We evaluated the impact of face mask usage rates and efficacy parameters on the effective  
186 reproduction number for  $R_0 = 2.5$  and  $R_0 = 6.0$ , to represent the impact of highly contagious  
187 variants of concern (e.g., B.1.617.2) (Figure 4) [24]. Note that warmer colors corresponding to  
188 higher effective reproduction numbers are visible in the lower left-hand corner of the right panel  
189 but less so in the left panel. As we approach 100% source control and wearer protection  
190 efficiencies, masks reduce effective reproduction number  $< 1$  for the low  $R_0$  scenario, but not for  
191 the high  $R_0$  scenario, given the same wearing percentages used to generate Figure 2. For  
192 example, when the baseline  $R_0 = 2.5$ , an effective reproduction number of 1 is achieved by a  
193 hypothetical mask with source control and wearer protection efficacies of 84% and 60%,  
194 respectively. However, these same efficacies would result in an effective reproduction number of  
195 2.33 when the baseline  $R_0 = 6.0$ , as is likely the case with the Delta variant of concern. Those  
196 efficacies for masks are achievable with common cloth masks and medical procedure masks if  
197 they are doubled up, if the cloth masks have filter inserts, or if either type of mask is overfit with  
198 a fitter or brace to ensure a tighter fit [29-31]. If source control efficacy is 96% and wearer  
199 protection efficacy is  $> 70\%$  (in line with efficacies for properly worn N95 respirators) then the  
200 effective reproduction numbers  $< 1.0$  ( $R_0 = 2.5$ ) and  $= 2.19$  ( $R_0 = 6.0$ ). Similarly, adoption of  
201 medical procedure masks (source control efficacy 56%, wearer protection efficacy 28%), results  
202 in effective reproduction numbers of 1.30 ( $R_0 = 2.5$ ) and 2.98 ( $R_0 = 6.0$ ). Please note that in  
203 Figure 4, even when source control and wearer protection efficacies of masks are zero, there is

204 still some small measure of containment due to the reduced contact rates of those who are  
205 detected and infected (whether symptomatic or asymptomatic) in the simulation.

206

207 **Discussion:**

208 Our results highlight the potential for substantial reduction in SARS-CoV-2 transmission, even  
209 with moderately effective masks, when they are worn consistently correctly (over the chin and  
210 covering nose and mouth) and/or per manufacturers' specifications by a large portion of the  
211 population. These findings underscore the potential impact of population-wide measures that can  
212 control transmission from infected individuals who do not have symptoms, both pre-  
213 symptomatic individuals who are infectious prior to developing symptoms and individuals who  
214 never experience symptoms. By extending the Worby and Chang model, we evaluated the  
215 impact of different face mask use by age and highlight the need for wide adoption of these  
216 interventions. Pairing this modeling framework with laboratory-derived parameters for source  
217 control efficacy of different types of face masks helps to more accurately compare the relative  
218 efficacy of each mask type as an intervention. Even with more specific source control  
219 parameterization, the results are generally consistent with previous modeling studies [10, 11]:  
220 face masks with realistic source control efficacy can reduce transmission substantially, and  
221 widespread adoption can mitigate transmission at the population level. Furthermore, if the most  
222 common types of face mask – cloth and medical procedure masks – can be enhanced with more  
223 recent recommendations to improve fit around the nose and mouth, such as braces, elastic fitters,  
224 or even double masking, those substantial reductions can be improved upon.

225

226 Our study and several others suggest that the magnitude of reduction in SARS-CoV-2  
227 transmission increases non-linearly with increased mask usage. The reasons for the non-linear  
228 multiplier effect are several, at least including potential epidemiological, immunological, and  
229 behavioral mechanisms [17, 27, 31, 32]. Non-linear terms are inherent in the mathematical  
230 mechanism of transmission reduction, given that masks act as both source control on the infected  
231 and personal protection on the susceptible, terms which are multiplied together in the  
232 transmission equations. This can be seen in the curvature of the line graphs of Figure 3 as mask  
233 usage increases (diminishing returns can be seen as mask usage increases towards 100% in  
234 Figure 3A for the N95 respirators, however). Furthermore, it is hypothesized that there are non-  
235 linear effects inherent in the pathogenesis of SARS-CoV-2 infection, in that masks reduce the  
236 initial viral exposure even if a wearer becomes infected despite the mask, decreasing the severity  
237 of infection, reducing viral load and shedding, and increasing the asymptomatic ratio [17, 32,  
238 33]. If this hypothesis is substantiated and we ignore complications arising from a higher  
239 asymptomatic rate (i.e., more challenges with case identification), then there are potentially  
240 several non-linear terms describing how the reproduction number decreases with mask efficacy  
241 and use. Lastly, analysis of data on behavioral correlates of face mask use shows that people  
242 wear face masks more often when they see others do so, even when they already intended to  
243 wear a mask [28]. If changes in behavior were modeled, this would add another favorable non-  
244 linear term to the impact of mask wearing.

245

246 The pandemic literature does contain a minority of reports that do not confirm the efficacy of  
247 masks, although these studies have some important limitations. In particular, commentaries have  
248 been written about the methodological limitations of a recent publication by Bundgaard et al. that

249 appears to question the efficacy of face masks [34]. [35, 36]. Specifically, the study was only  
250 powered to test if the wearer protection efficacy of medical procedure masks (referred to as  
251 “surgical masks” in Bundgaard et al.) was >50% and was not designed to measure their effect as  
252 source control (because it was estimated only 5% of the population were wearing masks at the  
253 time of the study). The Bundgaard et al. results were underpowered to detect wearer protection  
254 efficacies of medical procedure and cloth masks. This is similar to another randomized  
255 controlled trial (RCT) of cloth face masks as wearer protection against influenza virus infection  
256 among healthcare workers by MacIntyre et al. [2]: the study was designed to evaluate only the  
257 wearer protection effectiveness, not the source control effectiveness. Critically, the MacIntyre et  
258 al. study did not compare cloth masks to no mask, only to masks of the health workers’ choosing,  
259 potentially including medical procedure masks. Hence, this RCT *in a healthcare setting* did not  
260 have the negative control of not wearing a mask to help inform definitive conclusions about the  
261 efficacy of cloth face masks for the general population in non-healthcare settings. In fact, a  
262 follow-up study by MacIntyre et al. in 2020 found that healthcare workers whose cloth masks  
263 were laundered by the hospital were protected as well as those who wore medical masks [37].  
264 Also, recent results from an epidemiological study [38] analyzing population level mask  
265 mandates where masks are more widely used are much more positive regarding the effectiveness  
266 of masks.

267

268 **Limitations:**

269 Despite widespread usage of masks and other mitigation strategies [39], transmission of SARS-  
270 CoV-2 remains inadequately controlled in the United States. There are many potential reasons  
271 why surveillance data and ecologic field studies might not show the magnitude of reduction in

272 infections due to increasing mask usage predicted here. The parameters used in the models  
273 developed here might need to be better calibrated to match local transmission probabilities when  
274 individuals contact one another (either through direct physical contact, e.g. through a handshake  
275 or kiss, or a proximal, two-way conversation consisting of 3 or more words). Also, surveys  
276 indicating mask usage in the population may have overestimated adherence over time or the  
277 proper use or maintenance of masks. We model mask use as a set of parameters that can vary by  
278 age, but not by other societal subgroups, and our age groups were only divided into  $\geq 65$  years  
279 and  $< 65$  years. Furthermore, our model does not distinguish between differing contact rates  
280 within relevant populations such as schools, workplace, and households, but instead uses U.S.-  
281 national estimates for contact rates.

282 The source data for mask efficacy used in these models were derived from controlled laboratory  
283 simulations and not from human experiments. Measurements by other groups of filtration  
284 efficiency using actual human volunteers tend to show more variation, and in some cases the  
285 efficacies are lower than those reported here [40, 41].

286 Other limitations of the study are that mask usage is not assumed to vary over time, although it is  
287 likely that consistent and correct mask use may increase or decrease over time as individuals  
288 change their behaviors. Thus, we model homogeneous and unchanging mask use in a limited  
289 number of subgroups vs. the reality that mask wearing is heterogeneous according to mask type,  
290 sub-population, maintenance and proper use, and many other time-varying characteristics. This  
291 may result in over-estimation of the impact of face masks on the pandemic. If so, even higher  
292 mask uptake would be necessary to achieve substantial reductions in cases than is indicated here.

293 Although the post-holiday 2020-2021 surge in cases seems large given a fairly high rate of mask  
294 usage, we have no solid counterfactual information for comparison [12], i.e. we do not know  
295 what the results would have been with no mask usage.

296 **Conclusions:**

297 Modeling studies, including this analysis, have estimated how face masks can reduce  
298 transmission of SARS-CoV-2 and make a major impact at the population level, even with  
299 varying levels of adherence and effectiveness of masks. Multiple public health interventions are  
300 needed to reduce the transmission of SARS-CoV-2 and, as our analysis shows, robust use of face  
301 masks is an important contributor. Face masks of various materials have the potential to  
302 substantially reduce transmission in the SARS-CoV-2 pandemic, depending on the type and fit of  
303 mask and the percentage adoption in the population. Furthermore, by attempting a more exact  
304 quantitation of the impact of masking, studies like this can show, for example, that for highly  
305 contagious new variants, such as the Delta variant of concern, masks alone are not enough to  
306 contain the outbreak, and other control strategies are needed (e.g. social distancing, hand  
307 washing, and vaccination). Public outreach and policies encouraging mask wearing, especially  
308 highly efficacious masks, need to be encouraged along with other prevention strategies. In fact,  
309 this study suggests that the current, imperfect use of masks has likely already reduced both cases  
310 and deaths.

311

312

313

314 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not  
315 necessarily represent the official position of the Centers for Disease Control and Prevention  
316 (CDC).

317 **Declarations:**

318 **Ethics approval and consent to participate:** No human subjects were used in the study,  
319 therefore no consent was needed.

320 **Consent for publication:** All authors consent to the publication. The paper has been cleared for  
321 publication by the CDC. The pre-print version of this article is present on  
322 <https://www.medrxiv.org/content/10.1101/2021.04.21.21255889v1>.

323 This article is not published nor is under publication elsewhere.

324 **Availability of data and material:** R code is available upon request.

325 **Competing interests:** All authors declare no competing interests.

326 **Funding:** All authors are employees of the CDC – no external funding was needed.

327 **Authors' contributions:** BMG, ANH, and RBS conceived the study. BMG and ANH did the  
328 background research and wrote the primary draft of the manuscript. ANH served as the primary  
329 statistician for the project, adapted and modified the models and methods, and programmed the  
330 models and equations in R. BMG and Prabasaj Paul served as secondary statisticians and  
331 provided critical review of the models and equations, and BMG provided some ancillary models  
332 and equations. BMG and ANH contributed equally to the paper. All authors helped pull  
333 together the parameters needed for the models from the primary literature and other sources, and  
334 all authors contributed to writing and critical review of the final manuscript.

335 **Author details:** <sup>1</sup>Office of Science, Deputy Director for Public Health Science and Surveillance,  
336 CDC, and Departments of Electrical and Computer Engineering and Industrial and Systems  
337 Engineering at the Georgia Institute of Technology; <sup>2</sup>Division of Tuberculosis Elimination,  
338 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, and Department  
339 Biostatistics and Bioinformatics Department, Rollins School of Public Health, Emory University;  
340 <sup>3</sup>CDC COVID-19 Response Team

341 **Acknowledgements:** The authors would like to thank all reviewers at the CDC who added to  
342 the clarity of the final manuscript, as well as other members of the CDC COVID-19 Response  
343 Modeling and Analytics Task Force for helpful discussions.

344

345

346 **Supplement:**

347 ***Methods***



348 Transmission of SARS-CoV-2 is modeled by a system of ordinary differential equations (ODE)  
 349 and compartments corresponding to age, disease status, and mask-wearing status. Compartments  
 350 comprise susceptible ( $S$ ), exposed ( $E$ ), pre-symptomatic ( $P$ ), asymptomatic and undetected ( $A_u$ ),  
 351 asymptomatic and detected ( $A_d$ ), symptomatic ( $I$ ), recovered ( $R$ ), and deceased ( $D$ ). The total  
 352 population is  $N = S + E + P + A_u + A_d + I + R$ . Initially,  $N = 100,000$ . Each of these compartments  
 353 is further stratified by age (16 age groups from the POLYMOD study) and mask-wearing status  
 354 (yes/no). Thus, each disease compartment is represented by a  $16 \times 2$  matrix, with entries  
 355 corresponding to the number of individuals of that particular disease status in age group  $i =$   
 356  $1, \dots, 16$  and with mask status  $j = 0$  (no mask),  $1$  (mask). In matrix form, the ODE system is:

357  
 358  
 359

$$\begin{aligned} \dot{S} &= -q \left\{ M((I + p_{\text{rel inf}} A_d) \cdot [1_{16} \ r1_{16}] + p_{\text{rel inf}}(P + A_u)) / N \begin{bmatrix} 1 & 1-w \\ 1-s & (1-w)(1-s) \end{bmatrix} \right\} \cdot S \\ \dot{E} &= q \left\{ M((I + p_{\text{rel inf}} A_d) \cdot [1_{16} \ r1_{16}] + p_{\text{rel inf}}(P + A_u)) / N \begin{bmatrix} 1 & 1-w \\ 1-s & (1-w)(1-s) \end{bmatrix} \right\} \cdot S \\ &\quad - \nu_E E \\ \dot{P} &= \nu_E E - \nu_P P \\ \dot{A}_d &= p_{\text{asym}} p_{\text{detect}} \nu_P \left( P + (p_{\text{inf mask use}} \cdot P) \begin{bmatrix} -1 & 1 \\ 0 & 0 \end{bmatrix} \right) - \nu_A A_d \\ \dot{A}_u &= p_{\text{asym}} (1 - p_{\text{detect}}) \nu_P P - \nu_A A_u \\ \dot{I} &= (1 - p_{\text{asym}}) \nu_P \left( P + (p_{\text{know}} p_{\text{inf mask use}} \cdot P) \begin{bmatrix} -1 & 1 \\ 0 & 0 \end{bmatrix} \right) - \nu_I I \\ \dot{R} &= \nu_A (A_d + A_u) + (1 - p_{\text{death}}) \nu_I I \end{aligned}$$

360

361 Dot superscript denotes derivative with respect to time; central dot  $\cdot$  indicates pointwise  
 362 multiplication of matrices of the same dimension, or of the columns of a matrix by a vector of  
 363 the same dimension.

364 Compartment durations are specified by a rate  $\nu_J$ , where  $J$  is the compartment. Average duration  
365 in a compartment is  $1/\nu_J$ . These rates model the durations of days exposed (2 days), pre-  
366 symptomatic (4 days), asymptomatic (9 days), and symptomatic (9 days). Relative infectiousness  
367 of pre-symptomatic and asymptomatic persons compared to symptomatic persons is  $p_{\text{rel inf}} = 0.75$ .  
368 Detection probability of an asymptomatic case is  $p_{\text{detect}} = 0.05$  and the proportion of  
369 asymptomatic infections is  $p_{\text{asym}} = 0.30$ . The risk of death for symptomatic individuals was  
370 inferred from age-specific infection fatality ratios (IFR) via the equation  $\text{CFR} = \text{IFR}/(1 - p_{\text{asym}})$ ,  
371 where CFR denotes the case fatality ratio. IFRs are 0.00003 for ages 0-19 years, 0.0002 ages 20-  
372 49, 0.005 ages 50-69, 0.054 ages 70 and older. These parameters are based on the September  
373 2020 estimates included in the CDC Pandemic Planning Scenario #5 [23]. We further assume  
374 that 20% of symptomatic individuals know that that they are sick with SARS-CoV-2 and we  
375 denote this fraction by  $p_{\text{know}}$ . These people put on a mask.

376 POLYMOD daily contact rates were obtained from the study by Prem *et al.* [21]. The raw matrix  
377 of contact rates was adjusted in the usual fashion to maintain balance (numbers of contacts of  
378 age group  $i$  with age group  $j$  same as that of  $j$  with  $i$ ). The raw matrix  $C$  is transformed to  $C'$  by

379

$$380 \quad C'_{ij} = \frac{1}{2}(C_{ij} + C_{ji}N_j/N_i)$$

381

382 where  $N_i$  is the population size of age group  $i$ . Age distribution of the population was based on  
383 American Community Survey (ACS) estimates for the U.S. population [42]. Matrix  $C'$  is, in  
384 turn, transformed to give the symmetric matrix  $M$  in the ODEs by

385 
$$M_{ij} = \frac{N_i}{2}(C_{ij}/N_j + C_{ji}/N_i) = C'_{ij}/(N_j/N)$$

386 In this formulation, a typical term in the force of infection (FoI) arising from an age-stratified  
387 infectious compartment  $J = P, A_d, A_u, I$  of a given mask status is

388

389

390

$$(MJ)_i/N = \sum_{k=1}^m M_{ik}J_k/N = \sum_{k=1}^m C'_{ik}J_k/N_k$$

391

392

393 where  $m = 16$  is the number of POLYMOD age groups corresponding to 5-year age bands  
394 ranging from younger than 5 years old to 70-75 years old, with the oldest age group comprising  
395 persons 75 years and older. The FoI is further stratified in the ODEs above depending on mask  
396 status. This is implemented by the  $2 \times 2$  matrix appearing in the differential equations for  $S$  and  
397  $E$ . This matrix governs reductions in the FoI according to source control efficacy (sce, or  $s$  for  
398 brevity) and wearer protection efficiency (wpe, or  $w$ ) conferred by the mask type. These combine  
399 in four ways depending on the mask status of the infector and infectee (e.g.,  $1 - wpe$  and  $1 - sce$   
400 multiply together in the case of transmission by mask wearers to mask wearers). We further  
401 assume that symptomatic and detected, asymptomatic people who wear a mask have a lower,  
402 daily rate of contact. As contact rates in compartmental models apply to susceptible, not  
403 infectious, individuals, we model this as a reduction in infectiousness by a proportion  $r$  for both  
404 symptomatic and detected, asymptomatic mask-wearers. Specifically, if subscript  $i$  indexes age  
405 group and superscripts ‘none’ and ‘mask’ denote no mask and mask wearing, respectively,  
406 expanding the matrix formulation of the ODEs for susceptible individuals gives

407

$$\begin{aligned}\dot{S}_i^{\text{none}} &= -q \sum_{k=1}^m M_{ik} (K_k^{\text{none}} + (1 - \text{sce}) K_k^{\text{mask}}) \times S_i^{\text{none}} / N \\ \dot{S}_i^{\text{mask}} &= -q(1 - \text{wpe}) \sum_{k=1}^m M_{ik} (K_k^{\text{none}} + (1 - \text{sce}) K_k^{\text{mask}}) \times S_i^{\text{mask}} / N\end{aligned}$$

408

409

410 where  $K^{\text{none}} = I^{\text{none}} + p_{\text{rel inf}} (P^{\text{none}} + A_d^{\text{none}} + A_u^{\text{none}})$  and

411  $K^{\text{mask}} = r I^{\text{mask}} + p_{\text{rel inf}} (P^{\text{mask}} + r A_d^{\text{mask}} + A_u^{\text{mask}})$ .

412 The age-specific vector  $p_{\text{inf mask use}}$  (in the set of 7 ODEs specified at the beginning of this  
413 supplement) specifies the proportion of symptomatic and detected asymptomatic people who don  
414 a mask upon learning they are infectious. The corresponding proportion for symptomatic  
415 individuals is  $p_{\text{know}} \times p_{\text{inf mask use}}$ . The  $2 \times 2$  matrix appearing in the differential equations for  $A_d$   
416 and  $I$  governs the adoption of masks by asymptomatic individuals when they are detected (the  
417 first column corresponds to no mask, the second to mask wearing). In simulations, we assumed  
418 that individuals aged 65 years and older adopted masks at one proportion and younger than 65  
419 years at another, lower, proportion (but this can be changed by the user). Expanding the matrix  
420 formulation of the ODEs for detected asymptomatic individuals gives

$$\begin{aligned}\dot{A}_{d,i}^{\text{none}} &= p_{\text{asym}} p_{\text{detect}} \nu P (1 - p_{\text{inf mask use},i}) P_i^{\text{none}} - \nu_A A_{d,i}^{\text{none}} \\ \dot{A}_{d,i}^{\text{mask}} &= p_{\text{asym}} p_{\text{detect}} \nu P (P_i^{\text{mask}} + p_{\text{inf mask use},i} P_i^{\text{none}}) - \nu_A A_{d,i}^{\text{mask}}\end{aligned}$$

421

422 It is assumed that a proportion of the general population (susceptible individuals) wear a mask at  
423 the outset and keep it on at all times (or at least when mixing in the population). This proportion  
424 can vary by age. We assume that in the general population, 80% of those aged 65 and older and  
425 60% of the rest, wear a mask (and keep it on indefinitely).

426 To seed the epidemic, we arbitrarily assumed that there were 10 detected, asymptomatic non-  
427 masked individuals in each age group at the outset. Time units were expressed in days. The  
428 model was run for 6 months (183 days) with a timestep of 0.25 days using a Runge-Kutta solver  
429 in R v.3.6.3 [43] using the package ‘deSolve’ [44].

430 The FoI was calibrated to yield a basic reproduction number  $R_0 = 2.5$  for the sub-model without  
431 mask usage. This yielded the parameter  $q = 0.01429$ , which represents the probability of a  
432 symptomatic infectious person infecting a susceptible person upon contact between them. The  
433 reproduction number was calculated as the dominant eigenvalue of the next-generation matrix  
434 (NGM) using the method of van den Driessche and Watmough [45]. Computation was facilitated  
435 by the R package ‘blockmatrix’ [46] owing to the sparseness of the matrices involved. Details of  
436 this calculation are described further below.

#### 437 ***Calculation of $R_0$***

438 Following [45], we construct matrices  $F$ , describing rates at which infectious individuals produce  
439 new infections, and  $V$ , consisting of all other rates, whose inverse describes average durations in  
440 compartments. The  $i$ th row and  $j$ th column of these matrices is the partial derivative of the right-  
441 hand side of the differential equation for compartment  $i$  with respect to compartment  $j$ , evaluated  
442 at the disease-free equilibrium (DFE). Only the 5 infected compartment types are considered,  
443 namely,  $E, P, A_d, A_u, I$ , enumerated by age group and mask status. The basic reproduction  
444 number  $R_0$  is given by the dominant eigenvalue of the NGM  $F V^{-1}$ .

445 Matrices  $F$  and  $V$  are of dimension  $160 \times 160$  (2 mask statuses  $\times$  16 age groups  $\times$  5 relevant  
446 compartment types). However, as new infections only arise from the  $E$  compartments, via the  
447 previously described FoI, matrix  $F$  is sparse. So too is  $V$ , as a lot of its sub-blocks are zero or

448 diagonal matrices. Hence, we can construct these matrices in block form. We use the Kronecker  
 449 product of matrices, which we denote by  $\otimes$ .

450 The DFE depends on the initial age-specific proportions,  $p_{\text{susc mask use}}$ , of the general, susceptible  
 451 population wearing a mask. Multiplying the ACS age group proportions pointwise by  $p_{\text{susc mask use}}$   
 452 and  $1 - p_{\text{susc mask use}}$  gives the age-specific proportions of the population with and without masks,  
 453 respectively. These are multiplied by the hypothetical total population size  $N = 100,000$  to obtain  
 454 numbers in each stratum.

455 Vectorizing the  $16 \times 2$  matrices in the ODEs by stacking columns into a single  $32 \times 1$  column  
 456 vector, we have the following constituent matrices for calculating  $R_0$ :

$$F_1 = \underbrace{\begin{bmatrix} 1 \\ 0 \\ 0 \\ 0 \\ 0 \end{bmatrix}}_{5 \times 1} \otimes \left\{ \left( \left( \underbrace{\begin{bmatrix} 1 \\ 1-w \end{bmatrix}}_{2 \times 1} \otimes \underbrace{[0 \ p_{ri} \ p_{ri} \ p_{ri} \ 1]}_{1 \times 5} \otimes \underbrace{[1 \ 1-s]}_{1 \times 2} \right) \cdot \underbrace{G}_{2 \times 10} \right) \otimes \underbrace{(M \cdot p_{ACS})}_{16 \times 16} \right\} \cdot \underbrace{\begin{bmatrix} \mathbf{1}_{16} - p_{\text{smu}} \\ p_{\text{smu}} \end{bmatrix}}_{32 \times 1}$$

$$G = \begin{bmatrix} \mathbf{1}_5^T & r & \mathbf{1}_3^T & r \\ \mathbf{1}_5^T & r & \mathbf{1}_3^T & r \end{bmatrix}$$

457  
 458 For brevity,  $p_{r.i.}$  denotes  $p_{\text{rel inf}}$  above,  $p_{ACS}$  is the ACS population age distribution,  $p_{s.m.u.}$  denotes  
 459  $p_{\text{susc mask use}}$  above,  $w$  denotes WPE,  $s$  denotes SCE,  $\mathbf{1}_n$  is the  $n \times 1$  vector of 1's, and  $\cdot$  represents  
 460 pointwise multiplication by column. Matrix  $M$  is the POLYMOD-derived contact matrix  
 461 described earlier. It follows from the definition of Kronecker product that  $F_1$  is  $160 \times 160$ . The  
 462 order of entries in row or column vectors of length 5 corresponds to the compartment types  $E, P,$   
 463  $A_d, A_u, I$ . Thus, the  $5 \times 1$  vector on the left represents new infections only arising from  
 464 compartments of type  $E$  (component 1) and not from  $P, A_d, A_u, I$  (components 2 to 5) and its  
 465 occurrence renders  $F_1$  sparse. The  $1 \times 5$  row vector has components 2-4 as  $p_{\text{rel inf}}$ , indicating the  
 466 relative infectiousness of presymptomatic and detected and undetected asymptomatic individuals

467  $(P, A_d, A_u)$  compared to symptomatic individuals  $I$  (component 5). Row and column vectors of  
 468 length 2 correspond to mask efficacies. The vector  $p_{ACS}$  represents the population age-  
 469 distribution and the  $32 \times 1$  vector on the right denotes the age-specific general population mask  
 470 wearing proportions.

471 The matrix  $F$  is given by  $F = qF_1$ , where  $q$  is the calibration parameter representing the  
 472 probability of symptomatic infectious persons infecting susceptible persons upon contact  
 473 between them.

474 Matrix  $V$  may also be expressed in block form as:

475

$$V = \begin{bmatrix} V_{EE} & 0 & 0 & 0 & 0 \\ V_{PE} & V_{PP} & 0 & 0 & 0 \\ 0 & V_{A_dP} & V_{A_dA_d} & 0 & 0 \\ 0 & V_{A_uP} & 0 & V_{A_uA_u} & 0 \\ 0 & V_{IP} & 0 & 0 & V_{II} \end{bmatrix}$$

476

477 where each block is a  $32 \times 32$  matrix. Theory guarantees  $V$  is invertible. As with  $F$ , the order of  
 478 the component types in block rows and columns here is  $E, P, A_d, A_u, I$ . The nonzero blocks are as  
 479 follows, with parameter notation as given earlier, and  $I_n$  denoting the  $n \times n$  identity matrix:

$$\begin{aligned} V_{EE} &= \nu_E I_{32} \\ V_{PE} &= -\nu_E I_{32} \\ V_{PP} &= \nu_P I_{32} \\ V_{A_dP} &= -\nu_P p_{\text{detect}} p_{\text{asym}} B_A \\ \text{where } B_A &= \begin{bmatrix} \text{diag}(1 - p_{\text{inf mask use}}) & 0 \\ \text{diag}(p_{\text{inf mask use}}) & I_{16} \end{bmatrix} \quad (16 \times 16 \text{ blocks}) \\ V_{A_dA_d} &= \nu_A I_{32} \\ V_{A_uP} &= -\nu_P (1 - p_{\text{detect}}) p_{\text{asym}} I_{32} \\ V_{A_uA_u} &= \nu_A I_{32} \\ V_{IP} &= -\nu_P (1 - p_{\text{asym}}) B_I \\ \text{where } B_I &= \begin{bmatrix} \text{diag}(1 - p_{\text{know}} p_{\text{inf mask use}}) & 0 \\ p_{\text{know}} \text{diag}(p_{\text{inf mask use}}) & I_{16} \end{bmatrix} \quad (16 \times 16 \text{ blocks}) \\ V_{II} &= \nu_I I_{32} \end{aligned}$$

480

481 Blocks  $V_{XX}$  on the leading diagonal correspond to outflows from compartment type  $X$ . Off-  
482 diagonal blocks  $V_{XY}$  correspond to inflows from compartment type  $Y$  to compartment type  $X$ . The  
483  $B$  matrices correspond to the adoption of mask use (change of mask status) upon asymptomatic  
484 detection/symptomatic awareness, according to the age-specific proportion ( $p_{\text{inf mask use}}$ ) who do  
485 so. Denoting the dominant eigenvalue of a matrix by  $\rho$ , we have

$$486 \quad R_0 = \rho(F V^{-1}) = q \times \rho(F_1 V^{-1}).$$

487 Setting baseline  $R_0 = 2.5$  (no mask use), we calibrate  $q = 2.5 \div \rho(F_1 V^{-1})$ .

### 488 *Computation of symptomatic and asymptomatic detection rates*

489 The percentage of symptomatic and asymptomatic SARS-CoV-2 cases that are detected are not  
490 established numbers, but they are suspected to be low given the general detection rate of 16.1%  
491 [47, 48]. Both can be estimated with a simple Bayesian calculation, however, given the general  
492 detection rate ( $P(\text{case})$  in the equation below), the asymptomatic rate of infections of 0.3 [23],  
493 and the probability that detected cases are and remain asymptomatic (0.2) or symptomatic (0.8)  
494 [49]. For example, the probability that a person becomes a detected case (e.g. through contact  
495 tracing efforts) given the person is asymptomatic is given below

$$496 \quad P(\text{case}|\text{asymptomatic}) = P(\text{asymptomatic}|\text{case}) P(\text{case})/P(\text{asymptomatic})$$

497 The simple calculation yields a 10.7% detection rate for asymptomatic individuals, and a 18.3%  
498 detection rate for those with symptoms. The 18.3% figure appears to be in line with  
499 epidemiological estimates as well [50].

### 500 **References:**

501



- 502 1. Brosseau, L.M., and Sietsema, M., *Commentary: Masks-For-All for Covid-19 Not Based on Sound*  
503 *Data (University of Minnesota)*. 2020.
- 504 2. MacIntyre, C.R., et al., *A cluster randomised trial of cloth masks compared with medical masks in*  
505 *healthcare workers*. *BMJ Open*, 2015. **5**(4): p. e006577.
- 506 3. Bae, S., et al., *Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled*  
507 *Comparison in 4 Patients*. *Ann Intern Med*, 2020. **173**(1): p. W22-w23.
- 508 4. Bai, Y., et al., *Presumed Asymptomatic Carrier Transmission of COVID-19*. *JAMA*, 2020. **323**(14):  
509 p. 1406-1407.
- 510 5. Centers for Disease Control and Prevention. *Considerations for Wearing Masks*. 2020 December  
511 18, 2020; Available from: [https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html)  
512 [sick/cloth-face-cover.html](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html).
- 513 6. Byambasuren, O., et al., *Estimating the extent of asymptomatic COVID-19 and its potential for*  
514 *community transmission: systematic review and meta-analysis*. *JAMMI*, 2020.
- 515 7. Poletti, P., et al., *Probability of symptoms and critical disease after SARS-CoV-2 infection*. *arXiv*.
- 516 8. Oran, D.P. and E.J. Topol, *Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative*  
517 *Review*. *Ann Intern Med*, 2020. **173**(5): p. 362-367.
- 518 9. Johansson, M.A., et al., *SARS-CoV-2 Transmission From People Without COVID-19 Symptoms*.  
519 *JAMA Network Open*, 2021. **4**(1): p. e2035057-e2035057.
- 520 10. Ngonghala, C.N., et al., *Mathematical assessment of the impact of non-pharmaceutical*  
521 *interventions on curtailing the 2019 novel Coronavirus*. *Math Biosci*, 2020. **325**: p. 108364.
- 522 11. Eikenberry, S.E., et al., *To mask or not to mask: Modeling the potential for face mask use by the*  
523 *general public to curtail the COVID-19 pandemic*. *Infect Dis Model*, 2020. **5**: p. 293-308.
- 524 12. Fisher, K.A., et al., *Factors Associated with Cloth Face Covering Use Among Adults During the*  
525 *COVID-19 Pandemic - United States, April and May 2020*. *MMWR Morb Mortal Wkly Rep*, 2020.  
526 **69**(28): p. 933-937.
- 527 13. Konda, A., et al., *Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth*  
528 *Masks*. *ACS Nano*, 2020. **14**(5): p. 6339-6347.
- 529 14. Lindsley, W.G., et al., *Efficacy of face masks, neck gaiters and face shields for reducing the*  
530 *expulsion of simulated cough-generated aerosols*. *Aerosol Science and Technology*, 2020: p. 1-  
531 12.
- 532 15. Payne, D.C., et al., *SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy*  
533 *Service Members - USS Theodore Roosevelt, April 2020*. *MMWR Morb Mortal Wkly Rep*, 2020.  
534 **69**(23): p. 714-721.
- 535 16. Hendrix, M.J., et al., *Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After*  
536 *Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020*.  
537 *MMWR Morb Mortal Wkly Rep*, 2020. **69**(28): p. 930-932.
- 538 17. Ing, A.J., C. Cocks, and J.P. Green, *COVID-19: in the footsteps of Ernest Shackleton*. *Thorax*, 2020.  
539 **75**(8): p. 693-694.
- 540 18. Lyu, W. and G.L. Wehby, *Community Use Of Face Masks And COVID-19: Evidence From A Natural*  
541 *Experiment Of State Mandates In The US*. *Health Aff (Millwood)*, 2020. **39**(8): p. 1419-1425.
- 542 19. Brooks, J.T. and J.C. Butler, *Effectiveness of Mask Wearing to Control Community Spread of*  
543 *SARS-CoV-2*. *Jama*, 2021. **325**(10): p. 998-999.
- 544 20. Worby, C.J. and H.H. Chang, *Face mask use in the general population and optimal resource*  
545 *allocation during the COVID-19 pandemic*. *Nat Commun*, 2020. **11**(1): p. 4049.
- 546 21. Prem, K., A.R. Cook, and M. Jit, *Projecting social contact matrices in 152 countries using contact*  
547 *surveys and demographic data*. *PLoS Comput Biol*, 2017. **13**(9): p. e1005697.
- 548 22. Mossong, J., et al., *Social contacts and mixing patterns relevant to the spread of infectious*  
549 *diseases*. *PLoS medicine*, 2008. **5**(3): p. e74-e74.

- 550 23. Centers for Disease Control and Prevention. *COVID-19 Pandemic Planning Scenarios*. 2020  
551 September 10, 2020; Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html)  
552 [ncov/hcp/planning-scenarios.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html).
- 553 24. Volz, E., et al., *Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking*  
554 *epidemiological and genetic data*. 2021: p. 2020.12.30.20249034.
- 555 25. Chan, J.F., et al., *Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a*  
556 *Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19)*. Clin Infect Dis, 2020.  
557 **71**(16): p. 2139-2149.
- 558 26. Ueki, H., et al., *Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2*.  
559 mSphere, 2020. **5**(5).
- 560 27. Centers for Disease Control and Prevention. *Interim Infection Prevention and Control*  
561 *Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19)*  
562 *Pandemic*. 2020 December 14, 2020; Available from: Interim Infection Prevention and Control  
563 Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19)  
564 Pandemic.
- 565 28. Barile, J.P., et al., *Theory-based Behavioral Predictors of Self-reported Use of Face Coverings in*  
566 *Public Settings during the COVID-19 Pandemic in the United States*. Ann Behav Med, 2020.
- 567 29. Gandhi, M. and L.C. Marr, *Uniting Infectious Disease and Physical Science Principles on the*  
568 *Importance of Face Masks for COVID-19*. Med, 2021. **2**(1): p. 29-32.
- 569 30. Rothamer, D.A., et al., *Strategies to minimize SARS-CoV-2 transmission in classroom settings:*  
570 *Combined impacts of ventilation and mask effective filtration efficiency*. 2021: p.  
571 2020.12.31.20249101.
- 572 31. Brooks, J.T., et al., *Maximizing Fit for Cloth and Medical Procedure Masks to Improve*  
573 *Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021*. MMWR Morb Mortal  
574 Wkly Rep, 2021. **70**(7): p. 254-257.
- 575 32. Gandhi, M. and G.W. Rutherford, *Facial Masking for Covid-19 - Potential for "Variolation" as We*  
576 *Await a Vaccine*. N Engl J Med, 2020. **383**(18): p. e101.
- 577 33. Sims, M.D., et al., *COVID-19 seropositivity and asymptomatic rates in healthcare workers are*  
578 *associated with job function and masking*. Clin Infect Dis, 2020.
- 579 34. Bundgaard, H., et al., *Effectiveness of Adding a Mask Recommendation to Other Public Health*  
580 *Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled*  
581 *Trial*. Ann Intern Med, 2020.
- 582 35. Laine, C., S.N. Goodman, and E. Guallar, *The Role of Masks in Mitigating the SARS-CoV-2*  
583 *Pandemic: Another Piece of the Puzzle*. Ann Intern Med, 2020.
- 584 36. Frieden, T.R. and S. Cash-Goldwasser, *Of Masks and Methods*. Ann Intern Med, 2020.
- 585 37. MacIntyre, C.R., et al., *Contamination and washing of cloth masks and risk of infection among*  
586 *hospital health workers in Vietnam: a post hoc analysis of a randomised controlled trial*. BMJ  
587 Open, 2020. **10**(9): p. e042045.
- 588 38. Van Dyke, M.E., et al., *Trends in County-Level COVID-19 Incidence in Counties With and Without*  
589 *a Mask Mandate - Kansas, June 1-August 23, 2020*. MMWR Morb Mortal Wkly Rep, 2020.  
590 **69**(47): p. 1777-1781.
- 591 39. Hutchins, H.J., et al., *COVID-19 Mitigation Behaviors by Age Group - United States, April-June*  
592 *2020*. MMWR Morb Mortal Wkly Rep, 2020. **69**(43): p. 1584-1590.
- 593 40. Clapp, P.W., et al., *Evaluation of Cloth Masks and Modified Procedure Masks as Personal*  
594 *Protective Equipment for the Public During the COVID-19 Pandemic*. JAMA Intern Med, 2021.  
595 **181**(4): p. 463-469.

- 596 41. Mueller, A.V., et al., *Quantitative Method for Comparative Assessment of Particle Removal*  
597 *Efficiency of Fabric Masks as Alternatives to Standard Surgical Masks for PPE*. Matter, 2020. **3**(3):  
598 p. 950-962.
- 599 42. U.S. Census Bureau, *American Community Survey*, T. S0101, Editor. 2019, U.S. Census Bureau:  
600 data.census.gov.
- 601 43. R Core Development Team, *A language and environment for statistical computing.*, R.F.f.S.  
602 Computing., Editor. 2020.
- 603 44. Soetaert, K., T. Petzoldt, and R.W. Setzer, *Solving Differential Equations in R: Package deSolve*.  
604 2010, 2010. **33**(9): p. 25 %J Journal of Statistical Software.
- 605 45. van den Driessche, P. and J. Watmough, *Reproduction numbers and sub-threshold endemic*  
606 *equilibria for compartmental models of disease transmission*. Math Biosci, 2002. **180**: p. 29-48.
- 607 46. Cordano, E., *blockmatrix: Tools to solve algebraic systems with partitioned matrices*. R package  
608 version 1.0. 2014.
- 609 47. Alroy, K.A., et al., *Population-Based Estimates of Coronavirus Disease 2019 (COVID-19)-like*  
610 *Illness, COVID-19 Illness, and Rates of Case Ascertainment, Hospitalizations, and Deaths—*  
611 *Noninstitutionalized New York City Residents, March–April 2020*. Clinical Infectious Diseases,  
612 2021.
- 613 48. Phipps, S.J., R.Q. Grafton, and T. Kompas, *Robust estimates of the true (population) infection*  
614 *rate for COVID-19: a backcasting approach*. R Soc Open Sci, 2020. **7**(11): p. 200909.
- 615 49. Buitrago-Garcia, D., et al., *Occurrence and transmission potential of asymptomatic and*  
616 *presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis*. PLOS  
617 Medicine, 2020. **17**(9): p. e1003346.
- 618 50. Smith, L.E., et al., *Adherence to the test, trace, and isolate system in the UK: results from 37*  
619 *nationally representative surveys*. BMJ, 2021. **372**: p. n608.
- 620 51. Li, B., et al., *Viral infection and transmission in a large, well-traced outbreak caused by the SARS-*  
621 *CoV-2 Delta variant*. medRxiv, 2021: p. 2021.07.07.21260122.
- 622 52. Zhang, M., et al., *Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B.1.617.2*  
623 *– Guangdong Province, China, May – June 2021*. China CDC Weekly, 2021. **3**: p. 584-586.
- 624 53. Herlihy, R., et al., *Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -*  
625 *Mesa County, Colorado, April-June 2021*. MMWR Morb Mortal Wkly Rep, 2021. **70**(32): p. 1084-  
626 1087.
- 627 54. European Centre for Disease Prevention and Control, *Implications for the EU/EEA on the spread*  
628 *of the SARSCoV-2 Delta (B.1.617.2) variant of concern - 23 June 2021*. 2021, ECDC: Stockholm,  
629 Sweden.

## 630 Address for Correspondence:

631 Brian M. Gurbaxani, PhD. Address: 1600 Clifton Rd NE, Atlanta, GA 30333. Email:

632 [buw8@cdc.gov](mailto:buw8@cdc.gov).

633 Andrew N. Hill, PhD. Address: 1600 Clifton Rd NE, Atlanta, GA 30333. Email: [fyu7@cdc.gov](mailto:fyu7@cdc.gov).

## 634 Tables

635 **Table 1:** Parameter values used in the simulation



Infection Fatality Ratio (IFR) (IFR's for Delta VOC $\approx$ 2x shown for other SARS-CoV-2) [53, 54]	Ages 0–19: 0.00003 Ages 20–49: 0.0002 Ages 50–69: 0.005 Ages 70+: 0.054 [23]
Reduction in contact rate for symptomatic and detected asymptomatic persons wearing a mask	50%
Risk of death for symptomatic cases	See Supplement for calculation

636

637 **Table 2:** Incidence rate ratios (IRR) at 2-month intervals of new infections among masked vs.  
 638 non-masked population. Each row represents a scenario in which all mask-wearing individuals  
 639 are assumed to wear the specified type of mask. Wearer protection efficacy is assumed to be half  
 640 of source control efficacy. It assumes 60% of the susceptible population <65 years old are  
 641 wearing masks, 80% of those  $\geq$ 65 years old wear masks, and both rates increase 10% for both  
 642 detected and infected persons (whether symptomatic or asymptomatic).

	2 months	4 months	6 months
Type of Mask	IRR		
N95 respirator	0.47	0.47	0.47
Medical procedure	0.66	0.66	0.68

<b>Cloth</b>			
<b>Mask</b>	0.69	0.7	0.72
<b>Gaiter</b>	0.69	0.7	0.72
<b>Bandana</b>	0.76	0.78	0.8

643 IRR=Incidence rate ratio

## 644 **Figure Legends**

645 **Figure 1:** Schematic of compartmental model. Compartments are susceptible (S, green),  
646 exposed (E, yellow), infectious compartments (pre-symptomatic P, asymptomatic and detected  
647  $A_d$ , asymptomatic and undetected  $A_u$ , symptomatic I, pink), recovered (R, gray), and died (D,  
648 gray). Superscript 'n' denotes no mask, and 'm' denotes mask.

649 **Figure 2:** Heat maps of the percentage reduction in cumulative infections at the end of 1 year  
650 relative to no mask use in the population, assuming a baseline  $R_0 = 2.5$ . Assumes 60% of the  
651 susceptible population <65 years old are wearing masks, 80% of those  $\geq 65$  years old wear  
652 masks, and both rates increase 10% for detectably infected persons (whether symptomatic or  
653 asymptomatic). The simulation posits that 18.3% of symptomatic infected people and 10.7% of  
654 asymptomatic infected individuals have been detected by screening and are known to be carrying  
655 SARS-CoV-2 (see the Supplement). Mask efficacy parameters for source control and wearer  
656 protection increase along the vertical and horizontal axes, respectively. Reductions in  
657 cumulative infections over 6 months are shown on the left; reductions in deaths are shown on the  
658 right.


659 **Figure 3:** The percentage reduction in cumulative infections after 6 months of simulation,  
660 relative to no mask use in the population, as mask use varies in the general, susceptible  
661 population for different types of face masks. Mask source control parameters are fixed

662 according to estimates for the given types, and wearer protection efficiency is assumed to be half  
663 of source control effectiveness. In this analysis, younger susceptible persons are assumed to use  
664 masks at 70% of the rate of persons  $\geq 65$  years old. Known infected people  $\geq 65$  years old are  
665 masked at a 90% rate, with younger persons at 70%. The baseline  $R_0$  in the absence of mask use  
666 is assumed to be 2.5 in the left panel and 6.0 in the right panel.

667 **Figure 4:** Effective reproduction number for given mask use by varying efficacy parameters  
668 shown on the horizontal and vertical axes. This analysis assumes 90% and 70% mask use rates  
669 for infectious and detected persons older and younger than 65 years of age, respectively, and  
670 80% and 60% among susceptible persons for the same age breakdown. Asymptomatic detection  
671 and symptomatic awareness fractions are given in Table 1. The baseline  $R_0$  in the absence of  
672 mask use is assumed to be 2.5 in the left panel and 6.0 in the right panel.

673






674

675

676 **Figure 1**

677





678

679

680 **Figure 2**


681


682

683

684 **Figure 3**

685





686

687 **Figure 4**